In an about-face, Forest Laboratories ($FRX) says it will continue to sell its original version of the Alzheimer's treatment Namenda into the fall of 2014, rather than taking it off the market in August. The company had planned to discontinue the original formula to push patients onto its newer, extended-release version Namenda XR. Now the company, in the process of being acquired by Actavis ($ACT), says voluntary switching is going well, and it's making progress on the manufacturing side to make sure the XR version can meet demand. Release